Uso de la octreótida en ascitis refractaria después de un trasplante hepático

  1. Oana Anisa Nutu 1
  2. Alejandro Manrique Municio 1
  3. Alberto A. Marcacuzco Quinto 1
  4. Jorge Calvo Pulido 1
  5. Luis Carlos Jiménez Romero 1
  1. 1 Hospital Universitario 12 de Octubre. Madrid
Revista:
Revista Española de Enfermedades Digestivas

ISSN: 2340-416 1130-0108

Any de publicació: 2019

Volum: 111

Número: 11

Pàgines: 882-884

Tipus: Article

DOI: 10.17235/REED.2019.6316/2019 DIALNET GOOGLE SCHOLAR

Altres publicacions en: Revista Española de Enfermedades Digestivas

Resum

Refractory ascites is a condition associated with a reduced survival and a poorer quality of life. Portal hyperflow after liver transplantation is one of the main causes. We report the case of a female patient with refractory ascites after liver transplantation who was treated with splenic embolization. Ascites persisted despite embolization due to splenic revascularization by short gastric vessels and repeat embolization was technically unfeasible. Based on pathophysiology data, she was treated with octreotide, a somatostatin octapeptide analog, which resulted in splanchnic vasoconstriction and a reduction of the portal flow and venous pressure. After four months of treatment with octreotide, the patient had a good clinical status without ascites.